Company Overview and News

 
CSC Steel 1H profit below expectations on higher costs

2018-08-21 theedgemarkets
CSC Steel Holdings Bhd (Aug 20, RM1.30) Maintain hold with a lower target price (TP) of RM1.34: CSC Steel Holdings Bhd’s net profit for the first half of its financial year 2018 (1HFY18) of RM21 million came in below expectations, accounting for 36.1% and 41.7% of our and street’s full-year estimates.
5094

 
Trading ideas: PIE Industrial, MFM, Star Media, Pharmaniaga, CSC Steel

2018-08-20 thestar.com.my
KUALA LUMPUR: PIE Industrial Bhd , Malayan Flour Mills Bhd (MFM), Star Media Group Bhd , Pharmaniaga Bhd and CSC Steel Holdings Bhd are among the stocks to watch on Monday, according to JF Apex Research.
6084 5094 8192 3662

 
CSC Steel's profit falls in 2Q as costs rise

2018-08-17 theedgemarkets
KUALA LUMPUR (Aug 17): CSC Steel Holdings Bhd announced today a 28% year-on-year decline in net profit in its second quarter ended June 30, 2018 (2QFY18), after being hit by higher transportation costs and a significant drop in sales of higher margin products.
5094

 
Steel sector to be hit by more global headwinds, says MIDF Research

2018-08-13 theedgemarkets
KUALA LUMPUR (Aug 13): Malaysia's steel sector is likely to experience further headwinds, as global demand is likely to be further hit by shaky demand from China's waning construction sector, in addition to risks from trade war tariffs, said MIDF Amanah Investment Bank Bhd Research.
5797 5665 6556 5094 5087 9199

 
Steel manufacturers in a tight spot

2018-08-08 theedgemarkets
LOCAL steel manufacturers have found themselves in a tight spot again. Steel product manufacturers in the downstream segment have been exploiting loopholes in local anti-dumping regulations to bring in flat steel products, specifically cold rolled coil (CRC), at prices too low for local steel manufacturers to match.
7020 5094 5087

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...